1. Signaling Pathways
  2. GPCR/G Protein
    MAPK/ERK Pathway
  3. Ras
  4. Ras Degrader

Ras Degrader

Ras Degraders (7):

Cat. No. Product Name Effect Purity
  • HY-153821
    PROTAC KRAS G12C degrader-2
    Degrader 98.45%
    PROTAC KRAS G12C degrader-2 (compound 432) is a modulator of K-Ras protein hydrolysis. PROTAC KRAS G12C degrader-2 is a bifunctional compound, which contain on one end a cereblon inhibitor of apoptosis proteins (IAP) and on the other end a moiety which binds KRAS.
  • HY-161235
    BTX-7312
    Degrader
    BTX-7312 is a SOS1 cereblon-based bifunctional degrader. BTX-7312 reduces downstream signaling markers, pERK and pS6, and displays antiproliferative activity in cells harboring various KRAS mutations.
  • HY-153412
    KRAS inhibitor-22
    Degrader
    KRAS inhibitor-22 (compound FB9/6B9) is a potent inhibitor of K-Ras. KRAS inhibitor-22 targets to Kras 4B(G12D) and (G12C), which can be used for cancer research.
  • HY-153880
    KRAS degrader-1
    Degrader
    KRAS degrader-1 (compound 1) is a potent KRAS degrader. KRAS degrader-1 target specific proteins for degradation through the autophagy-lysosomal degradation pathway.
  • HY-155356
    YN14
    Degrader
    YN14 is a KRASG12C proteolysis targeting chimera (PROTAC). YN14 is highly potent and selective KRASG12C degrader and induces a stable KRASG12C: YN14: VHL ternary complex with low binding free energy (ΔG). YN14 has antiproliferative effects and significantly inhibits KRASG12C-mutant cancer cell growth. YN14 leads to tumor regression with tumor growth inhibition (TGI%) rates more than 100 % in the MIA PaCa-2 xenograft model.
  • HY-153674
    PROTAC SOS1 degrader-4
    Degrader
    PROTAC SOS1 degrader-4 (compound 10) is a potent SOS1 degrader. PROTAC SOS1 degrader-4 shows antiproliferative activity.
  • HY-113680
    KY1022
    Degrader
    KY1022 is a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway. KY1022 can inhibit cellular EMT, metastasis and apoptosis. KY1022 can be used for the research of metastatic colorectal cancer.